Switch to:
More From Other Websites
5:40 am Novogen engages Novotech as the CRO to conduct its Phase 1 clinical study for Cantrixil,... Nov 24 2015
Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial Nov 23 2015
Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia Nov 11 2015
Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina Nov 10 2015
NOVOGEN LTD Financials Nov 05 2015
Novogen Applies for Long-Term Options Listing on ASX Sep 30 2015
Novogen Applies for Long-term Options Listing Sep 29 2015
Novogen (NVGN) Conducts Scientific Review of R&D Program Aug 31 2015
Novogen Announces The Outcome Of A Comprehensive Science Review Aug 30 2015
Newly Appointed Acting CEO Outlines Immediate Plans for Novogen Jul 29 2015
Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board Jul 21 2015
Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma Jul 16 2015
Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer Jul 13 2015
H.C. Wainwright: Time To Buy Novogen Jul 01 2015
Novogen Announces the Chairman's Address at the Company's General Meeting Jun 23 2015
Anisina on Track to Enter Clinic in 2016 Jun 23 2015
StockNewsNow.com Publishes New SNNLive Video Interview With Novogen Limited Jun 16 2015
Novogen to Present at Bio International Convention Philadelphia 2015 Jun 11 2015
Studies Confirm TRXE-009 Crosses the Blood-brain Barrier Jun 04 2015
Novogen Expands Board with Two New Appointments Jun 02 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership